Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Limited has revised the effective date for the appointment of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP). The appointment, initially set for August 10, 2026, has been postponed to August 17, 2026, due to personal reasons cited by Mr. Manocha. This update follows a previous intimation on July 23, 2026. Mr. Manocha brings over 33 years of experience in technology and life sciences transformation.

Solara Active Pharma Sciences Limited has announced the submission of its unaudited financial results for the quarter ended June 30, 2026. The results, which were approved by the Board of Directors at a meeting held on July 23, 2026, cover both standalone and consolidated financial statements. A limited review report from M/s. Deloitte Haskins & Sells, Chartered Accountants, has also been submitted. The financial results will be made available on the company's investor relations website.

Solara Active Pharma Sciences Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited. The report confirms that there has been no deviation or variation in the utilization of proceeds from its Rights Issue compared to the objects stated in the Letter of Offer. The Rights Issue, which involved equity shares, had a total issue size of ₹449.95 crore, with net proceeds of ₹446.95 crore being monitored by CRISIL. The company has declared that the utilization of funds aligns with the stated objectives, providing assurance to investors regarding the proper deployment of capital raised.

Solara Active Pharma Sciences Limited has informed the exchange that there has been no deviation or variation in the utilization of funds raised through its Rights Issue for the quarter ended June 30, 2026. The statement, as per SEBI Listing Regulations, was reviewed and approved by the Audit Committee. The funds raised amounted to ₹442.73 Crores. The utilization primarily included repayment of borrowings (₹333.61 Crores) and general corporate purposes (₹105.02 Crores), with the latter not exceeding the permissible limit.

Solara Active Pharma Sciences Ltd announced the appointment of Mr. Ajit Manocha as Chief Information Officer (CIO), effective August 10, 2026. Mr. Manocha will also be designated as part of the Senior Management Personnel (SMP) of the company. With over 33 years of experience, he is a global technology and Life Sciences transformation leader specializing in digital transformation, SAP, Industry 4.0, cybersecurity, and AI/ML initiatives within regulated industries. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.

Solara Active Pharma Sciences reported strong Q1'27 financial results, with overall revenues up 20% YoY to INR 3,843 Mn and EBITDA up 10% YoY to INR 635 Mn. Profit After Tax (PAT) stood at INR 163 Mn, marking the highest in the last eighteen quarters. The company's Base business (Ex-Ibuprofen) showed robust performance with revenues at INR 3,077 Mn (up 24% YoY) and EBITDA at INR 722 Mn (up 8% YoY), despite input cost pressures. The Ibuprofen business reported revenues of INR 765 Mn with an EBITDA loss of INR 87 Mn. Solara also reduced its net debt by INR 1,346 Mn to INR 4,795 Mn, achieving a Net debt to EBITDA ratio of approximately 1.9.

Solara Active Pharma Sciences Limited announced that its Board of Directors met on July 23, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results, along with the limited review report from Deloitte Haskins & Sells, have been submitted to the exchange. The financial information will also be available on the company's investor relations website. The meeting commenced at 12:00 PM and concluded at 1:05 PM.

Solara Active Pharma Sciences Limited announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved during a board meeting held on July 23, 2026. The company has submitted these results along with the Limited Review Report from its statutory auditors, Deloitte Haskins & Sells LLP. The financial results will also be made available on the company's investor relations website. The board meeting commenced at 12:00 PM and concluded at 1:05 PM.

Solara Active Pharma Sciences Ltd has announced that its Board of Directors will convene on July 23, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, encompassing both standalone and consolidated statements. Additionally, the company has informed that its trading window for designated persons will be closed from July 1, 2026, until 48 hours after the announcement of these financial results, in compliance with SEBI's Insider Trading Regulations. The company's website will also host this information.

Solara Active Pharma Sciences Ltd has approved the issuance of a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up equity shares who have not paid the outstanding call money. The notice, approved by the Rights Issue Committee on July 3, 2026, specifies that failure to pay the First Call (₹131.25) and/or Second and Final Call (₹112.50) by July 27, 2026, will result in the forfeiture of shares and any amounts already paid. Payment can be made online via https://rights.cameoindia.com/solaracallmoney2. This action is in accordance with the Companies Act, SEBI Regulations, and the Letter of Offer.